Loading...
•
Jun 30, 2020
CareDx Q2 2020 Earnings Report
Achieved strong growth and robust results from RemoTraC, demonstrating patient-focus and dedication.
Key Takeaways
CareDx reported a 33% year-over-year increase in total revenue, reaching $41.8 million for the quarter ended June 30, 2020. The company's net loss was $6.6 million, with a non-GAAP net income of $1.7 million.
Total revenue reached $41.8 million, a 33% increase year-over-year.
Over 17,100 AlloSure Kidney and AlloMap Heart patient results were provided, with over 40% originating from RemoTraC and mobile phlebotomy.
First-ever AlloCell revenue was recorded from a cell therapy partnership.
A successful public offering was completed, raising $134.6 million in net proceeds, increasing cash and cash equivalents to $211.4 million.
Revenue by Segment
Forward Guidance
Due to the continued uncertainties with respect to the COVID-19 pandemic, CareDx will not be providing guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...